title: The management of anemia in the myelodysplastic syndrome.
abstract: How to treat anemia in the myelodysplastic syndrome (MDS) is controversial. Many health care systems refuse to fund erythropoietin on grounds of health economics. A new paper on the effect of anemia in MDS on cardiac remodeling has suggested that a higher treatment threshold level for hemoglobin should be introduced. This would have an impact of the calculation of risk/benefits.
authors.forename: Terry J
authors.initials: TJ
authors.lastname: Hamblin
mesh_terms: D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000150:complications*
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin